Indication
Squamous Cell Carcinoma of Skin
3 clinical trials
4 products
Clinical trial
Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid TumorsStatus: Recruiting, Estimated PCD: 2024-01-01
Product
RAPA-201Clinical trial
A reTrOspective Study on Patient's Data From the French Cemiplimab Cohort ATU Programs Compared to Standard of Care in FranceStatus: Completed, Estimated PCD: 2022-09-30
Product
CemiplimabClinical trial
Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Product
IFX-1